Changes in lymphoid tissue proliferation with PD-1 inhibitor therapy for lung cancer using FLT-PET/MRI; a retrospective study

Changes in lymphoid tissue proliferation with PD-1 inhibitor therapy for lung cancer using FLT-PET/MRI; a retrospective study - Changes in lymphoid tissue proliferation with PD-1 inhibitor therapy for lung cancer using FLT-PET/MRI; a retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052404

Enrollment

Registered

2023-10-04

Start date

2021-12-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age 20 or over. 2) Patients with pathologically confirmed advanced non-small cell lung cancer (NSCLC), and indication of PD-1 immune checkpoint inhibitors (nivolumab or pembrolizumab). 3) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with metallic device in their body. 2) Patients with claustrophobia. 3) Pregnant or lactating woman. 4) Other cases attending physician it is determined unsuitable for registration of the study.

Design outcomes

Primary

Measure	Time frame
Percentage change in FLT accumulation in lymphoid tissues (spleen and bone marrow) before and after PD-1 inhibitor treatment and tumor response to PD-1 inhibitor treatment	—

Secondary

Measure	Time frame
Relationship between FLT accumulation and patient background (gender, age, height, weight, BMI, smoking history, comorbidities, previous treatment), blood test data and its rate of change (white blood cell count, neutrophil count, lymphocyte count, red blood cell count, hemoglobin, platelet count, RDW, CRP, T.bil, AST, ALT, LDH, BUN, Cr, albumin, tumor markers). Percentage change in FLT accumulation in lymphoid tissue before and after PD-1 inhibitor treatment and its association with progression-free survival and overall survival for PD-1 antibody treatment.	—

Measure

Time frame

Relationship between FLT accumulation and patient background (gender, age, height, weight, BMI, smoking history, comorbidities, previous treatment), blood test data and its rate of change (white blood cell count, neutrophil count, lymphocyte count, red blood cell count, hemoglobin, platelet count, RDW, CRP, T.bil, AST, ALT, LDH, BUN, Cr, albumin, tumor markers). Percentage change in FLT accumulation in lymphoid tissue before and after PD-1 inhibitor treatment and its association with progression-free survival and overall survival for PD-1 antibody treatment.

—

Countries

Japan

Contacts

Public ContactYukihiro Umeda

Faculty of Medical Sciences, University of Fukui Third Department of Internal Medicine

umeda@u-fukui.ac.jp+81776613111

Outcome results